Research & Development: Page 72
-
What's New
WHAT’S NEW NEW HEALTHCARERELATED PRODUCTS, SERVICES, AND COMPANIES Noonan Russo Communications has agreed to merge its operations with the public relations division of Euro RSCG Healthview, establishing a new company — Noonan Russo Presence Euro RSCG. The new entity, a differentiated communicatio...
By PharmaVoice Team • Oct. 30, 2009 -
PharmaTrax
Extending its line of therapeutic class research, NOP World Health has added Diabetes Patient Market Study to its portfolio of disease state research. The staff of diabetes experts who support the study, which has been produced by NOP World Health’s sister com pany, RoperASW since 1989, will be i...
By PharmaVoice Team • Oct. 30, 2009 -
Explore the Trendline➔
Stock via Getty ImagesTrendlineBig Pharma Business Strategies
Large pharmas are consistently tasked with the goal of growth. But in recent years, the upward trajectory has been littered with new hurdles.
By PharmaVoice staff -
Pharma Outlet
The pharmaceutical industry is facing a crucial short age in the area of clinical trials. With an estimated 4,360 new drugs in the pipeline, it has become an increasing challenge for the industry to recruit both qualified patient volunteers and experienced researchers. Only an estimated 5 million...
By Kathleen H. Drennan • Oct. 29, 2009 -
Brave New Digital World
Pharma companies must be bold and confident in their deployment of electronic solutions or risk being left behind on the technological superhighway. Patients and physicians are migrating in droves toward Web- and mobile-based healthcare solutions. The overall number of e-health consumers who go o...
By PharmaVoice Team • Oct. 27, 2009 -
What's Missing in eSolutions: Enabling the Redefinition of Clinical Development
There’s something missing from the eSolutions discussion. In fact, there are two key missing links: n eSolutions that are no more than bridges between silos will not meet the needs of a rapidly changing clinical development environment; and n Strategies, pilots, and initial use of eSolutions are ...
By PharmaVoice Team • Oct. 27, 2009 -
eClinical Feedback: Why Sponsors Need an Integrated, Closed-Loop Clinical Process
David Gemzik, Vice President, Implementation Services Sean Cheng, Senior Product Marketing Manager Faced with slowing pipe lines and spiraling costs in new drug development, sponsors in recent years have been trying to conquer the last frontier in process improvement: R&D. However, increasing...
By PharmaVoice Team • Oct. 27, 2009 -
Letter from the Editor
3 PUBLISHER Lisa Banket EDITOR Taren Grom CREATIVE DIRECTOR Marah Walsh DIRECTOR OF SALES Darlene Kwiatkowski CONTRIBUTING EDITORS Virginia Kirk Denise Myshko Elisabeth Pena Kim Ribbink Deborah Ruriani Lynda Sears Copyright 2002 by PharmaLinx LLC, Titusville, NJ Printed in the U.S.A. Volume Two, ...
By Taren Grom • Oct. 23, 2009 -
The Nose Knows
Many of the properties that make the nose an effective way for an illicit drug user to get a “fix” are actually qualities that doctors and patients are seeking for legitimate treatments — a noninjection form that delivers medication in highly targeted, quickly absorbed doses. Britannia Pharmaceut...
By Taren Grom • Oct. 23, 2009 -
PharmaTrax
$7 Billion in revenue predicted for ADVANCED DRUG DELIVERY SYSTEMS by 2005 The market for drugs employing advanced drug delivery technologies will surpass $7 billion by 2005,according to a study from Kalorama Information.The market segment has seen doubledigit growth over the past few years, and ...
By PharmaVoice Team • Oct. 23, 2009 -
Pharma Outlet
Despite a history of new product launches, strong growth, and increased research spending, it is clear that the pharmaceutical industry is in a period of major transition. The challenge facing the industry is one of creating a sustainable pipeline that can generate the longterm growth needed to f...
By Kevin Starr • Oct. 23, 2009 -
Table of Contents
on the cover High Stakes: HITECH The pharma industry could come out a winner in the new game of HITECH (Health Information Technology for Economic and Clinical Health Act), if companies can come up with the right ante. FEATURES Publication Planning Update Title VIII of FDAAA, which requires the p...
By PharmaVoice Team • Sept. 30, 2009 -
Christine Bunt: Converging on a Solution
Converging on a Solution Moving from diagnostics to pharmaceuticals, from Europe to the United States, and ultimately from big pharma to a small startup company is not for everybody. But Christine Bunt has the confidence, knowledge, and business acumen to take on any challenge, and she revels in ...
By Kim Ribbink • Sept. 28, 2009 -
Last Word
AstraZeneca’s Dr. Larry Furlong Outlines the Company’s Lean Sigma Program for Process Improvement AstraZeneca is applying the business improvement methodology Lean Sigma to discovery in an attempt to shorten project lead times and increase candidate quality. AstraZeneca’s Larry Furlong, Ph.D., i...
By PharmaVoice Team • Sept. 28, 2009 -
Talent Pool
Pharmaceutical POOL Dr. Per FALK Novo Nordisk Names Clinical Research Head for North America Novo Nordisk, a global healthcare company focusing on diabetes care, has appointed Per Falk, M.D., Ph.D., as VP for clinical, medical, and regulatory affairs for North America. Dr. Falk leads clinical res...
By PharmaVoice Team • Sept. 28, 2009 -
E-Media
New Electronic and Web-based Applications, Sites, and Technologies Featured Briefs: Inclinical, Terrosa Offer Collaborative CTMS Subscription Services Pharsight Offers PK Data Management Solution Compass Healthcare Leverages Social Media in Community Website IMS Health Speeds Access to Promotiona...
By PharmaVoice Team • Sept. 28, 2009 -
What's New
New Healthcare-related Products, Services, and Companies Featured Briefs: FDA Anticounterfeiting Draft Guidance Focuses on Chemical Identifiers inVentiv Renames Professional Development Business PCE Partners with ACU on Continuing Education for NPs, PAs Gullapalli Launches Patient-Centered CME Of...
By PharmaVoice Team • Sept. 28, 2009 -
PharmaTrax
Sales, marketing, And R&D?Trends affecting the healthcare industry Life-Sciences Companies Unprepared for Information Security Risks Despite the promise of the information age and the billions of dollars in economic stimulus funding, many life-sciences and healthcare companies have yet to mee...
By PharmaVoice Team • Sept. 28, 2009 -
The Knowledge Revolution
In 20 to 25 years, pharmaceutical research and development will be multidimensional. Scientists will use artificial intelligence and robotics and interact through a global networked Web. Modeling and simulations that work at different levels, including digital models of “virtual patients," will b...
By PharmaVoice Team • Aug. 24, 2009 -
Patient Recruitment: Strategies for Multinational Studies
Finding appropriate study subjects is still one of the biggest stumbling blocks for timely and efficient drug development. Recruiting patients for multinational trials can be even more daunting, since global trials add to the complexity. While experts say some issues are no longer an obstacle — s...
By Denise Myshko • Aug. 21, 2009 -
Last Word
Making the Connection How does the diversity program alliance between Centocor and the University of Michigan align with J&J’s overarching diversity programs? Barbosa: Within Centocor, as well as across Johnson & Johnson, there are fundamental principles that define the company and how we...
By PharmaVoice Team • Aug. 21, 2009 -
Talent Pool
talent pool executive appointments and promotions in the healthcare industry Pharmaceutical POOL Dr. Ann MILLER Steven SEMBLER Eisai Appoints Two Senior VPs Eisai Inc. has expanded its leadership roster with the hiring of two senior VPs. Ann Miller, M.D., joins Eisai as senior VP, primary care an...
By PharmaVoice Team • Aug. 21, 2009 -
PharmaTrax
Biopharma Firms Increasingly Seek Marketing Role in Licensing Deals Large pharmaceutical companies’ growing reliance on alliances and in-licensing to gain access to technologies and new molecular entities from biopharmaceutical firms has strengthened the bargaining position for firms offering the...
By PharmaVoice Team • Aug. 21, 2009 -
Raise Your Voice: Letters
Pricing: At What Cost In your March 2002 article “The Cost of Doing Business,” I criticized as incorrect the conclusion that high R&D costs cause high pharma prices. A more economically sensible conclusion is that high pharma prices cause companies to undertake higher cost, more diffi cult, a...
By PharmaVoice Team • Aug. 13, 2009 -
Letter from the Editor
PUBLISHER Lisa Banket EDITOR Taren Grom CREATIVE DIRECTOR Marah Walsh DIRECTOR OF SALES Darlene Kwiatkowski CONTRIBUTING EDITORS Diane Hoffman Virginia Kirk Denise Myshko Kim Ribbink Deborah Ruriani Lynda Sears Copyright 2002 by PharmaLinx LLC, Titusville, NJ Printed in the U.S.A. Volume Two, Num...
By Taren Grom • Aug. 13, 2009 -
The Creative Challenge
BY TAREN GROM CHARLENE PROUNIS Our clients are afraid to take risks. The original concept often gets very watered down and loses its flair.There are so many people who are involved in the decision making process, by the time an ad gets approved it’s defaulted to the lowest common denominator. Cha...
By PharmaVoice Team • Aug. 12, 2009